Clinical Trial Update: Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating whether contingent incentives plus bupropion improves smoking cessation in people with schizophrenia; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Tobacco Use Disorder

Drugs mentioned

• bupropion (bupropion)

Snippet

Sponsor: Brown University | Conditions: Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder | Phase 2 | Status: COMPLETED | Results posted: 2012-12-17